Treatment for COVID-19

Phase-Based Estimates
1
Effectiveness
1
Safety
Cardiology Unit, ASST-Fatebenefratelli Sacco, Luigi Sacco University Hospital, Milan, Italy, Milan, Italy
COVID-19+2 More
Eligibility
18+
All Sexes
Eligible conditions
COVID-19

Study Summary

This study is evaluating whether continuous cardiac rhythm monitoring may help determine the natural history of atrial fibrillation.

See full description

Eligible Conditions

  • COVID-19
  • Atrial Fibrillation
  • New-onset Atrial Fibrillation (NOAF)

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Study Objectives

This trial is evaluating whether Treatment will improve 3 primary outcomes and 2 secondary outcomes in patients with COVID-19. Measurement will happen over the course of 3 years.

3 years
AF Burden
AF Progression
Composite of all-cause mortality, stroke and bleeding
Time to adjudicated cardiovascular death
Time to adjudicated ischemic stroke/transient ischemic attack (TIA)/systemic arterial embolism

Trial Safety

Safety Estimate

1 of 3

Compared to trials

Trial Design

1 Treatment Groups

Control

This trial requires 200 total participants across 1 different treatment groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 3 years for reporting.

Who is running the study

Principal Investigator
A. N.
Andrea Natale, Executive Medical Director
Texas Cardiac Arrhythmia Research Foundation

Closest Location

Montefiore Medical Center - New York, NY

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Age> 18 years;
Confirmed infection with SARS-CoV-2;
Patients with a first clinical episode of AF ≥30 s at admission or during hospitalization for COVID-19;
implantation of an ILR, a PMK, or an ICD during COVID-19 hospitalization or within 30 days after hospital discharge, or an ILR, a PMK, or an ICD implanted before COVID-19 hospitalization.

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can covid-19 be cured?

Add answer

While there is no cure for covid-19, it can be controlled, which provides opportunities to treat other comorbidities. In the U.S. and China, at least one in every three infections is asymptomatic. Given the low fatality rate and the possible treatment options for serious illness, some are willing to accept these risks and treat asymptomatic patients. To further increase testing in patients without symptoms and to limit their number are steps we need to take to mitigate the spread.

Unverified Answer

What causes covid-19?

Add answer

There is currently very little known about the relationship between a virus and the immune system and the development of a severe infection such as this, but the symptoms of corona Virus and other health issues such as infection and poor hygiene can play a major role.\n

Unverified Answer

What are common treatments for covid-19?

Add answer

The management of acute and chronic disease and mental health in patients with and without chronic disease is not necessarily dependent on disease trajectory, disease severity, symptoms and presence of comorbidities, but rather on the patient's general health. However, patients are still prone to present with comorbidities, therefore, to further develop and promote good clinical care and management strategies.

Unverified Answer

How many people get covid-19 a year in the United States?

Add answer

There has been an outbreak in the United States that is suspected to have affected over half a million people. Most cases are mild to moderate with about 1.1 million new cases from November 1, 2019 to May 30, 2020. Of the reported cases, most (89.5%) occurred in persons between 20 and 69 years of age. Most cases occurred among those reporting no pre-existing comorbidities or underlying immunosuppression.

Unverified Answer

What are the signs of covid-19?

Add answer

There is very little information on the clinical signs and symptoms of viral infection and it should not be treated with any drug or symptomatic treatment as part of the management. Clinicians and general public should follow the clinical guidelines. The patient should be identified by the clinician. After they are identified, patient will be placed on a strict isolation method. However, the clinical management to stop infection and stop transmitting the disease is based on the epidemiological information from each region.

Unverified Answer

What is covid-19?

Add answer

Covid-19, often called the coronavirus disease (COVID-19), is a highly contagious new virus that causes the disease known as coronavirus disease (COVID-19). There is currently no vaccine or specific treatment for COVID-19. While a cure is not available, many people can recover.\n

Unverified Answer

Does treatment improve quality of life for those with covid-19?

Add answer

Quality of life for survivors of covid-19 is similar to normative data when covid-19 has been managed in clinical practice. Overall, HRQoL for survivors of covid-19 is comparable with general population norms. When covid-19 treatment is initiated early after clinical presentation, it significantly improves HRQoL.

Unverified Answer

What is the average age someone gets covid-19?

Add answer

Covid-19 is a disease that affects those of every age group. There was no particular risk of the disease based on age. Older people were disproportionately affected and should be a focus of further study.

Unverified Answer

What are the common side effects of treatment?

Add answer

The common side effects of treatment can be very mild to severe. They also take time to manifest but, unlike other severe side effects like heart failure, can resolve the patient's condition even if they last for several months. [Treatments to treat or cure infections can cause harm.] If you don't know what the side effects are, ask your doctor.\nquestion: Is it okay to use the internet to talk about cancer? answer: A 2014 study found that people were more positive about communicating online when it was "invisible," meaning they had not spoken in person about cancer in the previous six months.

Unverified Answer

What is the latest research for covid-19?

Add answer

This summary focuses on the scientific, medical, government, and public health perspectives on how the disease is being treated and controlled. Specific attention is given to the medical treatment (symptofis﬊s, potential for serious complications) and public and governmental policy issues related to the outbreak.

Unverified Answer

Is treatment safe for people?

Add answer

It was concluded that there was no indication for a new policy based in universal prescription of oseltamivir, an antiviral drug recommended for treatment of a confirmed infection in the last year.

Unverified Answer

What are the latest developments in treatment for therapeutic use?

Add answer

More effective and rapid drug therapies are being developed and refined. While some of these are effective in the short term and have been recommended by national medical authorities, the long-term effects of many of these treatments and the safety profiles are not fully characterized. [The latest developments in treatment for therapeutic use] are [relatively] recent; [some have only been in use for about a decade]. The safety of most medicines [are] still unclear and [further clinical trials] are generally needed.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for COVID-19 by sharing your contact details with the study coordinator.